Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modulating the immune system: a vaccine for glaucoma?

Michal Schwartz1

  • 1Department of Neurobiology, The Weizmann Institute of Science, Rehovot, Israel. Michal.Schwartz@weizmann.ac.il

Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie
|May 18, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disruption of the brain-spleen axis impairs monocyte-microglia communication and accelerates disease progression in a mouse model of amyloidosis.

Nature communications·2026
Same author

Parsing the functions of immediate-early proteins in the lytic-latent balance of HCMV infection.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Treating the immune system to repair the brain.

Science translational medicine·2026
Same author

Author Correction: Viral entry shapes HCMV latency establishment.

Nature communications·2026
Same author

Evolving brain-immunity: From Ramón y Cajal's mysterious butterflies to a garden sustained by immune cells as their nectar.

Neuron·2026
Same author

A cytomegalovirus-encoded lncRNA blocks cell-cycle progression.

Molecular cell·2026

A novel vaccine strategy uses the immune system to combat glaucomatous neuropathy progression by targeting disease-promoting factors. This approach aids in neuroprotection and supports optic nerve repair, offering a new avenue for managing this neurodegenerative condition.

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Immunology

Background:

  • Glaucomatous neuropathy is a complex neurodegenerative disease involving multiple molecular and cellular factors contributing to its progression.
  • These factors persist and drive pathology even after initial treatment, necessitating strategies for neuroprotection and restoration.

Purpose of the Study:

  • To investigate the potential of a vaccine-elicted immune response to mitigate glaucomatous neuropathy progression.
  • To explore a novel therapeutic approach for neuroprotection and optic nerve repair in glaucoma.

Main Methods:

  • Development of a vaccine using synthetic antigens (e.g., glatiramer acetate) designed for weak cross-reactivity with retinal and optic nerve self-antigens.
  • Induction of an immune response involving lymphocytes, microglia, and macrophages to target disease-associated factors.

Related Experiment Videos

Main Results:

  • The vaccine strategy aims to recruit immune effector cells to neutralize factors contributing to optic nerve destruction.
  • The induced immune response is expected to support cell renewal and repair processes within the optic nerve.

Conclusions:

  • A vaccine-induced immune defense offers a promising strategy to slow the progression of glaucomatous neuropathy.
  • This approach targets disease progression rather than onset, focusing on neuroprotection and restoration through immune system modulation.